METIS TECHBIO-P

7666
8.4651.26% ( +0.105 )
Delay Closed: Nov 16, 16:08:11

Overview

METIS TECHBIO-P (7666)

Metis TechBio Co., Ltd. engages in research and development of AI-empowered nanomaterial for the delivery and application of active agents across carbon-based l...

Open
8.110
High
8.650
Low
7.600
Prev. Close
8.360
Volume
9.19M
Turnover
75.08M
Avg Price
8.172
Bid/Ask Ratio
7.94%
Amplitude
12.56%
52wk High
29.980
Volume Ratio
6.61
Turnover Ratio
0.85%
52wk Low
7.600
HK Mkt Cap
9.17B
Market CapHKD
10.01B
P/ETTM
Loss
P/EDynamic
Loss
P/EStatic
--
EPSTTM
-0.344
EPSDynamic
-0.298
EPSStatic
--
BVPS
2.94
P/B
2.88
HK Shares
1.08B
Dividend YieldTTM
--
DividendTTM
--
Shares
1.18B
Min lot size
500
Currency
HKD

METIS TECHBIO-P Analyst Rating

View more

Forecast & Rating

Nov 3, 2026
Price forecast
HK$24.72191.99%
Forecast & RatingStrong buy
4analysts
  • Strong buy75.00%
  • Buy25.00%
  • Hold0.00%
  • Sell0.00%
  • Strong sell0.00%

Daily Events

  1. Nov, 16

    METiS TechBio (7666.HK) reversed an early slide on Monday, closing at HK$8.465, up 1.26% from HK$8.360, after dipping to HK$7.665, a fresh 52-week low, then rebounding to HK$8.595 intraday on HK$74.8 million turnover. The recent weakness traces to the cornerstone investor lock-up expiry, which drove a 12% single-day drop on Friday and a 24.89% weekly decline; today's move reads as a repair bounce after that supply cleared. Fundamentals contrast with the price action: Q2 2026 revenue reached HK$89.1 million, up more than 140-fold year on year, while the net loss narrowed 15.67% to HK$88.5 million, leaving net margin at -99.3% and per-share loss at HK$0.0972, with price-to-book at 2.88. The US$1.1 billion AI drug-delivery agreement with Eli Lilly remains the central narrative. At HK$8.465 the stock sits 71.76% below its 52-week high of HK$29.98, down 64.43% year to date, and well under its MA20 of HK$10.763 and MA60 of HK$13.61, though the post-lock-up overhang may still need absorbing.

  2. Nov, 13

    METiS TechBio (7666.HK) reversed early gains and weakened through the afternoon, closing at HK$8.36 versus HK$10.41 previously, a 19.69% drop, driven by concerns around the cornerstone investor lock-up expiring tomorrow and a continued fading of the excitement that followed October's US$1.1 billion AI drug-delivery pact with Eli Lilly. The stock opened at HK$10.00, briefly rebounded to HK$9.445 in the morning session, then slid to HK$8.08 in the afternoon, essentially matching yesterday's 52-week low of HK$8.075, on 31.63 million shares worth HK$283 million. Fundamentals run the other way: Q2 2026 revenue reached HK$89.1 million, up more than 140-fold year on year, while the net loss of HK$88.48 million narrowed 15.67% and the net margin stayed at -99.3%. The shares are down 64.87% year to date, 72.11% below the 52-week high of HK$29.98, and sit well beneath the MA20 of HK$10.94 and MA60 of HK$13.72. However, the absolute loss is still close to HK$88 million, with no clear timing yet on a turnaround.

  3. Nov, 12

    METiS TechBio (7666.HK) fell 6.55% to HK$10.41 on Thursday in a spike-and-fade session, dragged by the cornerstone investor lock-up expiring tomorrow: it opened at HK$11.40 and slid to an intraday low of HK$10.38 at 15:57 BJ on HK$424m turnover. The earlier US$1.1bn AI drug-delivery pact with Eli Lilly had lifted the shares 6% in one session, but that momentum has unwound; the stock is down 56.26% year-to-date, 65.28% below its 52-week high of HK$29.98 set on 12 May, only about 10% above the HK$9.46 low, and below both the MA20 of HK$11.08 and MA60 of HK$13.77. Fundamentals remain loss-making: Q2 revenue of HK$89.1m against a net loss of HK$88.5m, narrowed 15.67% yoy, with net margin at -99.30%, PB 3.54x and PE -30.25x. Still, rising revenue and a narrowing loss indicate the AI nano-materials platform is progressing commercially.

  4. Nov, 6

    Shares gapped down 2.6% to HK$10.50, probed lower, then rebounded to an intraday high of HK$11.12 at 10:21 BJ before consolidating between HK$10.85 and HK$11.05 in the afternoon session and closing at HK$10.99, down 2.57% on 2.356 million shares worth HK$25.7 million, a 0.24% turnover rate. The overhang is the approaching expiry of cornerstone investors' lock-up, with the stock named in November's Hong Kong unlocking list after already falling 6% the prior session; inclusion in the HKEX Artificial Intelligence Index, the US$1.1 billion AI-LNP order from Eli Lilly and AiLNP platform endorsement by an international pharmaceutical company failed to extend momentum. Q2 revenue reached HK$89.1 million against a net loss of HK$88.5 million, narrowing 15.67% yoy, while net margin stayed at -99.3% and PB at 3.74x, contrasting with a price still -53.82% YTD, 63.34% below the 52-week high of HK$29.98 and under both MA20 (11.416) and MA60 (13.871). It nonetheless sits 16.17% above the July 29 low of HK$9.46, though event-driven swings may persist until the unlocked shares are absorbed.

  5. Nov, 4

    An 8.1% gain to HK$11.10 lifted 7666.HK from a flat open to an intraday high of HK$11.42 at 14:33 BJ, powered by its addition to the HKEX Artificial Intelligence Index and follow-through from the US$1.1 billion AI-LNP order with Eli Lilly; morning trade idled between HK$10.32 and HK$10.78 before afternoon buying pushed the stock up, and it settled at HK$11.13 on 6.554 million shares worth HK$71.1 million. Q2 2026 revenue of HK$89.1 million, up more than 140-fold year on year, sits alongside a narrower net loss of HK$88.5 million (-15.67% yoy) and a still-negative 99.3% net margin, giving a PE of -32.25 and PB of 3.78. The rebound still leaves the shares down 53.36% year to date, 62.98% below the HK$29.98 52-week high and under both MA20 of HK$11.93 and MA60 of HK$13.91, though 17.34% above the HK$9.46 low. Still, the close gave back nearly HK$0.3 from the high, pointing to limited follow-through.

News

Bullish vs. Bearish — Last 3 Months

10.9k followers · 0 opinions
▲Bullish50%
50%Bearish▼
  • K
    Kinkajou

    $METIS TECHBIO-P(07666.HK)$METIS TECHBIO-P(07666.HK)thank you for great return

    图片 1,共 1 张
    Trade Showcase: Trade, Show & Earn Rewards!
  • K
    Kinkajou

    Its working well for me...

    Kinkajou 2026-09-2317:22:01 METIS TECHBIO-P 07666 P/L% +22.35% Market price 17.3
    Trade Showcase: Trade, Show & Earn Rewards!
  • Z
    Zhang Johnaten

    $METIS TECHBIO-P(07666.HK) What a lousy stock, keeps falling. Your management is useless and inactive, are you screwing over shareholders?